News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Raven Announces Preclinical Results on Lead Anticancer Monoclonal Antibody Demonstrating Strong Antitumor Activity Against Colon, Gastric, and Pancreatic Cancers


Posted on: 09/30/2004

Raven Announces Preclinical Results on Lead Anticancer Monoclonal Antibody Demonstrating Strong Antitumor Activity Against Colon, Gastric, and Pancreatic Cancers



Data Presented at EORTC-NCI-AACR Symposium in Geneva Supports Company's Plans to File IND Later This Year

SOUTH SAN FRANCISCO, Calif. and GENEVA, Sept. 30 /PRNewswire/ -- Raven biotechnologies, inc. announced today preclinical data was presented today on RAV12, its lead therapeutic monoclonal antibody for GI cancers. The data was presented during the EORTC-NCI-AACR Conference on "Molecular Targets and Cancer Therapeutics" in Geneva.

Greater than 90 percent of colon, stomach, and pancreatic patient tumor samples express the RAV12 carbohydrate epitope, as do a lower percentage of endometrial, ovarian, liver, lung and breast tumors.

"Based on these data, we anticipate filing an IND on RAV12 for the treatment of advanced stage adenocarcinoma later this year," said Jennie Mather, PhD, President and CEO of Raven. "The data presented at EORTC provide further support for the selection of RAV12 to enter into the clinic and validate the power of our discovery platform, which is focused exclusively on therapeutic antibodies for cancer."

Raven scientists presented the following abstract: "RAV12: A Glycotope- specific Chimeric Antibody That Exhibits Potent Cytotoxic Activity Against Gastrointestinal Tumor Cell Lines in vitro and in vivo." (Abstract # 297), Pryer, N.K, et al.

The researchers reported that RAV12 is directly cytotoxic against human colon cell lines in vitro and that the mechanism of action of RAV12 appears to involve the induction of oncotic cell death, characterized by cell and organelle swelling and loss of membrane integrity. RAV12 is highly efficacious in colon, gastric and pancreatic tumor xenograft models in vivo. RAV12 was well-tolerated in a repeat dose toxicology studies in other animal models.

More About RAV12 Therapeutic Antibody for Cancer

RAV12 is a high affinity IgG1 chimeric antibody recognizing a primate restricted N-linked carbohydrate epitope expressed on a number of human carcinomas, especially adenocarcinomas.

RAV12 was an antibody generated using Raven's proprietary cell biology- based drug discovery platform, which generates panels of monoclonal antibodies directed against cell-surface antigens present on cancer cells. By screening these candidate antibodies against human tumor tissues and cell lines, Raven identifies subsets of monoclonal antibodies that exhibit strong reactivity to a variety of solid cancers and bioactivity against tumor cell lines in vitro.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the simultaneous discovery of novel cell- surface drug targets and the antibody therapeutics to regulate them. Raven's integrated approach is based on proprietary, human tissue-specific progenitor and tumor stem cell lines developed at Raven, plus proprietary methods optimized for producing MAbs targeting cell-surface proteins. This platform rapidly identifies target antigens and therapeutic candidates in their native configuration in the intact cell membrane. The Company has identified candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. Raven's lead therapeutic candidate, RAV12 is currently in advanced preclinical development for gastrointestinal cancers including colorectal, gastric, and pancreatic.

SOURCE Raven biotechnologies, inc.

Web Site: http://www.ravenbio.com -------------------------------------------------------------------------------- More news from PR Newswire... Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Terms and conditions, including restrictions on redistribution, apply. Copyright © 1996-2004 PR Newswire Association LLC. All Rights Reserved. A United Business Media company. PR Newswire web sites - MEDIA - Media Site ProfNet - INFORMATION - Brazil Canada Europe North America Disclose eWatch™ (UK) eWatch™ (US) Media Insider MEDIAtlas™ MultiVu™ PR AUDiT - CLIENTS - PRN Direct - NEWS - Brazil Canada China Europe France Israel Netherlands North America


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740